Drug intelligence / Profile preview

KBD051

Development stage: Preclinical
Lead developer: Baiyu Pharmaceutical
Modality: Small Molecules

Overview

KBD051 is an investigational small molecule antagonist targeting Toll-like receptors 7 and 8 (TLR7/8), currently in development by Chengdu Baiyu Jingelai Pharmaceutical. The drug is designed to treat autoimmune diseases by inhibiting the activation of TLR7 and TLR8, which are pattern recognition receptors that play a crucial role in the innate immune system. By blocking these receptors, KBD051 aims to reduce the production of pro-inflammatory cytokines and Type I interferons, thereby mitigating the chronic inflammation associated with conditions such as systemic lupus erythematosus (SLE) and other immune-mediated disorders.

Targets

TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)

Beyond the preview

Go deeper on KBD051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KBD051.

Explore the full profile